Navigation Links
Solutia Reports First Quarter 2009 Results
Date:5/6/2009

Adjusted Earnings Per Share - Reconciliation of a Non-US GAAP Measure


                                                           Three Months
                                                              Ended
    (in $ millions, except per share data)                March 31, 2009
    --------------------------------------                --------------
    Loss from continuing operations before tax                  $(11)
    Non-GAAP Adjustments (1)                                      (1)
    ------------------------                                      --
    Adjusted earnings from continuing operations before tax      (12)
    Income tax benefit on adjusted earnings                        7
    ---------------------------------------                      ---
    Adjusted earnings for adjusted EPS                           $(5)
    ----------------------------------                           ---


    Diluted Shares (millions)
    -------------------------                                  -----
    Weighted average shares outstanding                        93.27
    Assumed conversion of Restricted Stock                      0.00
    Assumed conversion of Stock Options                         0.00
    -----------------------------------                         ----
    Total Diluted Shares                                       93.27
    --------------------                                       -----
    Adjusted EPS                                               (0.05)
    ------------                                               -----

    (1) See table of Summary of Events Affecting Comparability



                                    SOLUTIA INC.
                        CONSOLIDATED STATEMENT OF OPERATIONS
                  (Dollars in millions, except per share amounts)
                                    (Unaudited)

                                          Successor          Predecessor
          
'/>"/>
SOURCE Solutia Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
(Date:1/14/2014)... January 14, 2014 Kerr Corporation, a leading ... and additional how-to information about dual arch impressions on its ... Dual Arch Impressions,” the blog entry serves up a list ... houses a step-by-step demonstration by Dr. David Little as he ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in Altadena ... ideas for 2014 in production and sales of interactive ... high-quality, low-cost, DRM-free ebooks and to use the sales ... first major development will be bookstore sales in local ...
Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... 21, 2011 MO BIO Laboratories, Inc., ... purification, announces the launch of the RTS DNase™ Kit, ... enzyme. (Photo: http://photos.prnewswire.com/prnh/20110921/LA65994 ) ... from RNA preparations while protecting valuable RNA samples from ...
... Silence Therapeutics plc (AIM: SLN) ("Silence", the "Group" or ... company, today announces the appointment of Tony Sedgwick PhD, ... Sedgwick will be based in Silence,s London office and ... Tony Sedgwick is an experienced biotechnology and pharmaceutical ...
... SANTA CRUZ, Calif., Sept. 20, 2011 SomaGenics, Inc., ... data on the efficacy of RNA interference (RNAi) therapeutics ... sshRNA platform. SomaGenics, along with its ... in a poster entitled "Synthetic Short shRNAs are Potent ...
Cached Biology Technology:MO BIO Laboratories, Inc. Launches the RTS DNase™ Kit 2Appointment of Chief Business Officer 2Appointment of Chief Business Officer 3SomaGenics' sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus 2SomaGenics' sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus 3
(Date:4/24/2014)... published in the Scientific Reports journal. , CSIC ... joint centre of CSIC and Pompeu Fabra University-UPF), explains: "When ... we saw that it did not match with the DNA ... the complete genome and to make a functional interpretation in ... Louis XVI". , The functional genome analysis was based ...
(Date:4/24/2014)... Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich have identified ... system to discriminate between viral and endogenous RNAs ... they take control of cellular metabolism and hijack ... This process is dependent on viral RNA molecules ... of RNA viruses) and/or newly synthesized in the ...
(Date:4/24/2014)... State University and the University of North Carolina at ... could help identify arterial plaque that is at high ... stroke. , At issue is the plaque that builds ... plaque are deemed "vulnerable," meaning that they are more ... heart attack or stroke. , "Existing state-of-the-art technologies are ...
Breaking Biology News(10 mins):The blood preserved in the pumpkin did not belong to Louis XVI 2Viral infections: Identifying the tell-tale patterns 2Viral infections: Identifying the tell-tale patterns 3New ultrasound device may add in detecting risk for heart attack, stroke 2
... program that trains emergency medical service technicians (EMS) to read ... and expedite treatment for the severe heart condition known as ... attack, has excellent results and should become the standard of ... of the Canadian Journal of Cardiology . ...
... cells organized in thousands of small divots. Hit these cells ... candidate for a cancer drug. But a review published this ... argues that these 2D models in fact offer very ... and may often give researchers misleading results. "Up ...
... scientific research has deep roots in the history of ... off spectacularly from launch pads across the disciplines of ... and a sea change in a scientific culture now ... science, crowd-sourced science, DIY research, volunteer monitoring, community participatory ...
Cached Biology News:ECGs administered by paramedics can speed treatment for severe heart attacks 2ECGs administered by paramedics can speed treatment for severe heart attacks 33-D tumor models improve drug discovery success rate 23-D tumor models improve drug discovery success rate 3Inaugural cross-disciplinary Public Participation in Scientific Research conference 2
Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Phospho-Chk1 (Ser296) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
Biology Products: